300529 Stock Overview
Engages in the research, development, production, and sales of blood purification products for hemadsorption industry in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Jafron Biomedical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥30.06 |
| 52 Week High | CN¥39.24 |
| 52 Week Low | CN¥15.88 |
| Beta | 0.36 |
| 1 Month Change | -1.80% |
| 3 Month Change | 20.43% |
| 1 Year Change | 37.45% |
| 3 Year Change | -41.99% |
| 5 Year Change | -17.70% |
| Change since IPO | 29.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300529 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | -0.9% | -3.5% | -2.7% |
| 1Y | 37.4% | -9.6% | 11.8% |
Return vs Industry: 300529 exceeded the CN Medical Equipment industry which returned -10.4% over the past year.
Return vs Market: 300529 exceeded the CN Market which returned 9.7% over the past year.
Price Volatility
| 300529 volatility | |
|---|---|
| 300529 Average Weekly Movement | 8.9% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300529 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300529's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 2,780 | Fan Dong | www.jafroninternational.com |
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sales of blood purification products for hemadsorption industry in China and internationally. The company offers solutions for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, kidney, and liver diseases; HA series hemoperfusion cartridge, BS bilirubin adsorption column and DNA immunoadsorption column, hemoperfusion machine, and blood purification machine; and other products, such as hemodialyzer, hemodialysis concentrate, disinfectants, resin bandages, online hemodialysis powder bag/bucket, and adsorbable suture with needles.
Jafron Biomedical Co.,Ltd. Fundamentals Summary
| 300529 fundamental statistics | |
|---|---|
| Market cap | CN¥23.28b |
| Earnings (TTM) | CN¥804.47m |
| Revenue (TTM) | CN¥2.63b |
28.9x
P/E Ratio8.8x
P/S RatioIs 300529 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300529 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.63b |
| Cost of Revenue | CN¥508.40m |
| Gross Profit | CN¥2.12b |
| Other Expenses | CN¥1.32b |
| Earnings | CN¥804.47m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.04 |
| Gross Margin | 80.68% |
| Net Profit Margin | 30.56% |
| Debt/Equity Ratio | 49.1% |
How did 300529 perform over the long term?
See historical performance and comparisonDividends
1.3%
Current Dividend Yield39%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 17:02 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jafron Biomedical Co.,Ltd. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sophia Zhang | China Stock Investment Research Co. Ltd. (GZ500..com) |
| Shuo Song | Citic Securities Co., Ltd. |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |